


Increased risk of thrombosis in myeloproliferative neoplasms

January 16 2018



(HealthDay)—Patients with myeloproliferative neoplasms (MPNs) have

increased risk of arterial thrombosis and venous thrombosis across all age groups and MPN subtypes, according to a study published online Jan. 16 in the *Annals of Internal Medicine*.

Malin Hultcrantz, M.D., Ph.D., from Karolinska University Hospital and Karolinska Institutet in Stockholm, and colleagues examined the risk for arterial and venous thrombosis seen in patients with MPNs versus [control participants](#) in a population-based setting. Data were included for 9,429 patients with MPNs and 35,820 matched control participants in Sweden from 1987 to 2009, with follow-up to 2010.

The researchers found that, compared with control participants, for patients with MPNs, the hazard ratios for arterial thrombosis were 3.0, 2.0, and 1.5 at three months, one year, and five years, respectively. For venous thrombosis, the corresponding hazard ratios were 9.7, 4.7, and 3.2. Across all [age groups](#), the rate was significantly increased and was similar for MPN subtypes. In patients with MPNs, the five-year cumulative incidence of thrombosis showed an initial rapid increase followed by a smaller increase during follow-up. During more recent calendar periods, the hazard ratio for venous thrombosis decreased.

"Patients with MPNs across all age groups have a significantly increased rate of arterial and [venous thrombosis](#) compared with matched control participants, with the highest rates at and shortly after diagnosis," the authors write.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

[Editorial \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Increased risk of thrombosis in myeloproliferative neoplasms (2018, January 16)
retrieved 23 April 2024 from
<https://medicalxpress.com/news/2018-01-thrombosis-myeloproliferative-neoplasms.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.